Priyanka Sharma, MD

Professional Background

Dr. Priyanka Sharma is a Professor of Medicine at the University of Kansas Medical Center and assistant director of clinical research and co-program leader for the Drug Discovery, Delivery & Experimental Therapeutics program at the University of Kansas Cancer Center. She is the institutional principal investigator for South West Oncology Group (SWOG) and co-PI for MCA-KUCC NCORP grant.

Dr. Sharma received her medical degree from MS University of Baroda, India and proceeded to complete Internal Medicine residency, chief residency, and Hematology-Oncology fellowship at the University of Kansas Medical Center. Her research interests include clinical and translational research in triple-negative breast cancer (TNBC) and novel treatment strategies for metastatic breast cancer.

Dr. Sharma is recipient of several grants including American Society of Clinical Oncology (ASCO) Advanced Clinical Research Award, Mary-Kay Foundation grant and is principle investigator of several ongoing clinical trials with targeted agents.

Dr. Sharma is Vice-Chair of the South West Oncology Group (SWOG) Breast Committee, member of SWOG Board of Governors and member of NCI breast cancer steering committee.

• MBBS, University of Baroda, Baroda, Gujurat
• Internship, Rural Health Service and Obstetrics/Gynecology, Baroda Medical College, Baroda , Gujurat
• Internship, Community Health Service and Internal Medicine, Baroda Medical College, Baroda, Gujurat
• Residency, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Residency, Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Clinical Fellowship, Division of Hematology/Oncology, University of Kansas School of Medicine, Kansas City, KS

• American Board of Internal Medicine - Medical Oncology
• Kansas

• Southwest Oncology Group, SWOG Breast Committee, Vice Chair, 2018 - Present
• American Society of Clinical Oncology, American Society of Clinical Oncology, Member, 2001 - Present

---

Research

Overview

I am a Professor of Medicine in the Department of Internal Medicine, Division of Oncology, as well as the Assistant Director for Clinical Research within the University of Kansas Cancer Center (KUCC). I am the Vice-Chair of the SWOG Breast Committee and have been member of the SWOG Board of Governors since 2015. I am a member of the American Society of Clinical Oncology (ASCO) scientific program committee, for which I also serve as breast cancer track leader for 2018-2019. In addition to national and institutional leadership roles, I am very actively involved in clinical and translational breast cancer research. My long-term research goal is to delineate personalized treatment strategies for triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer. I serve as Translational PI of an ongoing CTEP-funded SWOG trial for patients with TNBC (S1416) and as PI of an active translational SWOG study (S9313c) which also focuses on TNBC. Outside of SWOG I have served as PI of several neoadjuvant therapeutic investigator-initiated trials for TNBC.

• DDIR/HRD status predicts response to chemoimmunotherapy in TNBC, Department of Defense, PI
• Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study., SWOG, PI
• Phase II trial of Neoadjuvant Carboplatin, Docetaxel plus Pembrolizumab in Stage I-III Triple-Negative Breast Cancer (NeoPACT), Merck & Co, Inc., PI
• Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer, Novartis Oncology and Gilead Sciences, PI
• Evaluation of BRCAness as Prognostic Marker in Triple Negative Breast Cancer Patients Treated with Adjuvant Anthracycline Based Chemotherapy, Breast Cancer Research Foundation, PI
• Phase I/II trial of Nab-Paclitaxel and BYL-719 in Women with HER2 Negative Locally Recurrent or Metastatic Breast Cancer, Novartis Oncology, PI

• Sharma, Priyanka, Kimler, Bruce., F., O'Dea, Anne, Nye, Lauren, Wang, Yen., Y., Yoder, Rachel, Staley, Joshua., M., Prochaska, Lindsey, Wagner, Jamie, Amin, Amanda., L., Larson, Kelsey, Balanoff, Christa, Elia, Manana, Crane, Gregory, Madhusudhana, Sheshadri, Hoffmann, Marc, Sheehan, Maureen, Rodriguez, Roberto, Finke, Karissa, Shah, Rajvi, Satelli, Deepti, Shrestha, Anuj, Beck, Larry, McKittrick, Richard, Pluenneke, Robert, Raja, Vinay, Beeki, Venkatadri, Corum, Larry, Heldstab, Jaimie, LaFaver, Stephanie, Prager, Micki, Phadnis, Milind, Mudaranthakam, Dinesh., Pal, Jensen, Roy., A., Godwin, Andrew., K., Salgado, Roberto, Mehta, Kathan, Khan, Qamar. 2021. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).. Clinical Cancer Research, 27 (4), 975-982. https://doi.org/10.1158/1078-0432.ccr-20-3646
• Rodler, Eve, Sharma, Priyanka, Barlow, William., E, Gralow, Julie., R, Puhalla, Shannon., L, Anders, Carey., K, Goldstein, Lori, Tripathy, Debu, Brown-Glaberman, Ursa., A, Huynh, Thu-Tam, Szyarto, Christopher., S, Godwin, Andrew., K, Pathak, Harsh., B, Swisher, Elizabeth., M, Radke, Marc., R, Timms, Kirsten., M, Lew, Danika., L, Miao, Jieling, Pusztai, Lajos, Hayes, Daniel., F, Hortobagyi, Gabriel., N. 2023. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet Oncology, 24 (2), 162-174. https://doi.org/10.1016/s1470-2045(22)00739-2
• Sharma, Priyanka, Barlow, William., E., Godwin, Andrew., K., Parkes, Eileen., E., Knight, Laura., A., Walker, Steven., M., Kennedy, Richard., D., Harkin, Denis., P., Logan, Gemma., E., Steele, Christopher., J., Lambe, Shauna., M., Badve, Sunil, Gökmen-Polar, Yesim, Pathak, Harsh., B., Isakova, Kamilla, Linden, Hannah., M., Porter, Peggy, Pusztai, Lajos, Thompson, Alastair., M., Tripathy, Debu, Hortobagyi, Gabriel., N., Hayes, Daniel., F.. 2019. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.. Journal of Clinical Oncology, 37 (36), 3484-3492. https://doi.org/10.1200/jco.19.00693
• Sharma, Priyanka, Stecklein, Shane., R., Yoder, Rachel, Staley, Joshua., M., Schwensen, Kelsey, O’Dea, Anne, Nye, Lauren, Satelli, Deepti, Crane, Gregory, Madan, Rashna, O’Neil, Maura., F., Wagner, Jamie, Larson, Kelsey., E., Balanoff, Christa, Kilgore, Lyndsey, Phadnis, Milind., A., Godwin, Andrew., K., Salgado, Roberto, Khan, Qamar., J., O’Shaughnessy, Joyce. 2024. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology, 10 (2), 227. https://doi.org/10.1001/jamaoncol.2023.5033
• Sharma, Priyanka, Klemp, Jennifer., R., Kimler, Bruce., F., Mahnken, Jonathan., D., Geier, Larry., J., Khan, Qamar., J., Elia, Manana, Connor, Carol., S., McGinness, Marilee., K., Mammen, Joshua., M., Wagner, Jamie., L., Ward, Claire, Ranallo, Lori, Knight, Catherine., J., Stecklein, Shane., R., Jensen, Roy., A., Fabian, Carol., J., Godwin, Andrew., K.. 2014. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Research and Treatment, 145 (3), 707-714. https://doi.org/10.1007/s10549-014-2980-0
• Connor, C.., S., Kimler, B.., F., Mammen, J.., M., McGinness, M.., K., Wagner, J.., L., Alsop, S.., M., Ward, C., Fabian, C.., J., Khan, Q.., J., Sharma, P.. 2015. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. Journal of Surgical Oncology, 111 (2), 198-202. https://doi.org/10.1002/jso.23790
• Sharma, P, Barlow, W, Godwin, A.., K., Pathak, H., Isakova, K, Hartman, AR, TImms, KM, Linden, JM, Tripathy, D., Hortobagyi, G.N, Hayes, D.., F.. 2017. Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313) [abstract]. Cancer Res, 77 (13 Suppl), Abstract nr 1776. http://cancerres.aacrjournals.org/content/77/13_Supplement/1776
• Yoder, Rachel, Kimler, Bruce., F., Staley, Joshua., M., Schwensen, Kelsey, Wang, Yen., Y., Finke, Karissa, O’Dea, Anne, Nye, Lauren, Elia, Manana, Crane, Gregory, McKittrick, Richard, Pluenneke, Robert, Madhusudhana, Sheshadri, Beck, Larry, Shrestha, Anuj, Corum, Larry, Marsico, Mark, Stecklein, Shane., R., Godwin, Andrew., K., Khan, Qamar., J., Sharma, Priyanka. 2022. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.. NPJ breast cancer, 8 (1), 80. https://doi.org/10.1038/s41523-022-00448-4
• Sharma, Priyanka, López-Tarruella, Sara, García-Saenz, Jose., Angel, Ward, Claire, Connor, Carol., S., Gómez, Henry., L., Prat, Aleix, Moreno, Fernando, Jerez-Gilarranz, Yolanda, Barnadas, Augusti, Picornell, Antoni., C., del Monte-Millán, Maria, Gonzalez-Rivera, Milagros, Massarrah, Tatiana, Pelaez-Lorenzo, Beatriz, Palomero, María., Isabel, González del Val, Ricardo, Cortes, Javier, Fuentes Rivera, Hugo, Bretel Morales, Denisse, Márquez-Rodas, Iván, Perou, Charles., M., Wagner, Jamie., L., Mammen, Joshua., M.V., McGinness, Marilee., K., Klemp, Jennifer., R., Amin, Amanda., L., Fabian, Carol., J., Heldstab, Jaimie, Godwin, Andrew., K., Jensen, Roy., A., Kimler, Bruce., F., Khan, Qamar., J., Martin, Miguel. 2017. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 23 (3), 649-657. https://doi.org/10.1158/1078-0432.ccr-16-0162
• Sharma, Priyanka, López-Tarruella, Sara, García-Saenz, José., Angel, Khan, Qamar., J., Gómez, Henry., L., Prat, Aleix, Moreno, Fernando, Jerez-Gilarranz, Yolanda, Barnadas, Agustí, Picornell, Antoni., C., Monte-Millán, María., del, González-Rivera, Milagros, Massarrah, Tatiana, Pelaez-Lorenzo, Beatriz, Palomero, María., Isabel, González del Val, Ricardo, Cortés, Javier, Fuentes-Rivera, Hugo, Morales, Denisse., Bretel, Márquez-Rodas, Iván, Perou, Charles., M., Lehn, Carolyn, Wang, Yen., Y., Klemp, Jennifer., R., Mammen, Joshua., V., Wagner, Jamie., L., Amin, Amanda., L., O’Dea, Anne., P., Heldstab, Jaimie, Jensen, Roy., A., Kimler, Bruce., F., Godwin, Andrew., K., Martín, Miguel. 2018. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clinical Cancer Research, 24 (23), 5820-5829. https://doi.org/10.1158/1078-0432.ccr-18-0585